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ABSTRACT
Objectives: To explore the prognostic role of CK19 expression in squamous cell 
carcinomas within a well-defined cohort of oral tongue cancer patients.
Methods: In our retrospective study, we investigated 129 patients with tongue 
cancer that had suitable material for inclusion in a tissue microarray (TMA). Where 
possible, samples were taken from central and peripheral regions of the tumor to 
generate a representative sample of the tumor. The expression level of CK19 was 
assessed by immunohistochemical staining.
Results: Expression of CK19 in squamous cell carcinoma of the tongue was 
identified as a negative predictor for overall survival (OS; p<0.000) and disease 
specific survival (DSS; p=0.001). No significant difference could be shown for disease 
free survival (DFS) between patients with positive and negative CK19 staining 
(p=.094).
Conclusion: This is the first description of the highly significant role of CK19 in 
a selective, organ specific head and neck cancer cohort. Our results are of special 
importance against the background that CK19 positive carcinomas revealed a 
significantly poorer prognosis and therefore emphasize its prognostic and possible 
diagnostic role in tongue cancer.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common type of malignancy worldwide 
[1] and also one of the most aggressive and invasive cancer 
types [2]. A common HNSCC hallmark is local invasion 
and metastasis to regional lymph nodes, accounting for up 
to 88% of patient mortality rate in the two years following 
metastatic disease development [3]. Despite the long-held 
notion of genomic instability in advanced disease stages, 
a recent study found no difference in the accumulation of 
mutations in tumors from patients with or without lymph 
node involvement [4]. This indicates that alterations 
other than mutations in signaling pathways likely account 
for the progression from primary tumor to invasive and 
metastatic disease. The contributions towards metastatic 
                  Research Paper
Oncotarget76152www.impactjournals.com/oncotarget
disease arise both from changes in the behavior of tumor 
cells and interactions with various stromal components in 
the tumor microenvironment [3].
In the past years, several efforts have been 
undertaken to define new biomarkers that will predict 
patient outcome and assist in patient-specific treatment 
adapted regimes [5, 6]. The identification of reliable 
tumor markers for HNSCC is expected to facilitate early 
diagnosis, predict prognosis as well as assist in therapy 
options and modifications of patients. Among this array 
of biomarkers Cytokeratin 19 and Cytokeratin-Fragment 
19 (CK19, CYFRA 21-1), have emerged as two of the 
promising prognostic biomarkers [7, 8].
Cytokeratins (CK) are structural proteins forming 
the subunits of epithelial intermediary filaments. Twenty 
different CK polypeptides have thus far been identified. 
They are subgrouped into type I (40-56.5 kDa) and type 
II (53-67 kDa). Type I are acidic (CKs 9-20), type II 
are neutral to basic (CKs 1-8) [9]. Due to their specific 
distribution patterns, they are eminently suitable for use 
as differentiation markers in tumor pathology. CK19 
protein is expressed in simple epithelia and their malignant 
counterparts. CYFRA 21-1 is released from malignant 
epithelial cells into human serum, tissue fluid, urine and 
saliva by a cleaving enzyme, caspase-3 during apoptosis 
[10] and can be detected with the aid of monoclonal 
antibodies. It has been shown to be a useful serum-based 
biomarker in lung and breast cancer [10, 11]. Moreover, 
CYFRA 21-1 is a prognostic-relevant marker for overall 
survival (OS) in metastatic colorectal cancer after selective 
internal radiation therapy [12].
Using CYFRA 21-1 to diagnose HNSCC has led 
to promising results. Wang et al. [13] showed in their 
meta-analysis that serum CYFRA 21-1 plays a role in the 
confirmation of HNSCC diagnosis, rather as a screening 
tool for HNSCC. Furthermore, they suggest that the level 
of CYFRA 21-1 indicates a positive correlation with 
the grade of differentiation and nodal status in HNSCC 
patients, and has a role in monitoring the success of 
therapy and follow up of patients [13]. In addition, an 
abrupt increase of CYFRA 21-1 in serial measurements 
during follow-up would likely indicate impending disease 
progression and provide early prognostic information, 
particularly with regards to tumor progression and 
metastatic formation in the individual HNSCC patient, 
regardless of the cut-off value. Therefore, the CYFRA 
21-1 serum level is a good marker for follow-up in 
patients with HNSCC. In this way, CYFRA 21-1 may turn 
out to be useful not only for diagnosing HNSCC but also 
for characterizing its prognosis, which will improve the 
comprehensive management of HNSCC patients [13]. 
These suggestions are also supported by Zhong et al. [14], 
who found that CK19-positive score (staining intensity) 
in distant tissue (defined as at least 2 cm away from 
the edge of the cancerous mass) is predictive of tumor 
recurrence and survival in oral squamous cell carcinoma. 
Some patients with positive CK19 expression in distant 
tissue suffered from tumor recurrence and died of this 
disease during the follow-up period. Tumor recurrence 
rate is higher and survival rate lower in patients with 
positive CK19 expression in distant tissue than in those 
with negative CK19 expression in distant tissue. It can be 
suggested that positive CK19 expression in distant tissue 
may predict a higher risk of tumor recurrence and poor 
survival [14].
The aim of this paper is to explore the prognostic 
role of CK19 within a well-documented cohort of patients 
with oral tongue cancer, excluding tumors of the tongue 
base.
RESULTS
The whole cohort consisted of 229 patients of which 
CK19 staining (positive versus negative) was available for 
129 patients. Table 1 lists the patient demographics and 
tumor characteristics.
We found that patients with positive CK19 
immunoreactivity had a statistically significant worse 
outcome with regards to OS than patients with negative 
CK19 immunoreactivity (p<0.000; Figure 1). We 
investigated the survival differences in more detail and 
stratified for several demographic and prognostic factors 
as shown in Table 2. We found significant differences in 
gender (men, log rank, p =.002), age (≥60 years, log rank, 
p =.001), smoking (yes, log rank, p =.017; no, log-rank, 
p =.015) alcohol (risk drinker, log rank, p =.012), tumor 
staging (pT2-4b, log rank, p =.022), nodal status (pN1-3a, 
log rank, p =.027) tumor grading (2, log rank, p =.009) and 
perineural invasion (no, log rank, p <.000).
Patients with positive CK19 immunoreactivity also 
had a significantly worse outcome regarding DSS than 
patients with negative CK19 immunoreactivity (p=0.001; 
Figure 2). In addition, DSS was affected by gender (men, 
log rank, p <.000), age (≥60 years, log rank, p =.001), 
smoking (yes, log rank, p =.040; no, log-rank, p =.010) 
alcohol (non risk drinker, log rank, p =.007), tumor staging 
(pT1, log rank, p =.011) and tumor grading (2, log rank, p 
=.036; Table 3).
There is still a significant difference in OS 
between patients with positive and negative CK19 
immunoreactivity, after adjustment for demographic (age, 
smoking and alcohol) and known prognostic factors (pT, 
pN, tumor grading) (p=.010, Exp(B)=2.0349, 95% CI 
1.231-4.482).
A Cox-Regression showed that alcohol (p=.026, 
Exp(B)=1.666, 95% CI 1.098-3.069) and tumor grading 
(p=.024, Exp(B)=1.916, 95% CI 1.0601-3.049) were 
significant predictors for the differences in OS between 
patients with positive and patients with negative CK19 
immunoreactivity, whereas in DSS no demographic or 
prognostic factor was a statistically significant risk factor.
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Table 1: Patient demographics and tumor characteristics. The Pearson’s Chi-Square test revealed only a strong 
association between the expression of CK19 and alcohol consumption
 Total N CK19 positive N (%) CK19 negative N (%) Pearson‘s Chi-Square
Total 129 41 (31.8) 88 (68.2)  
Age    p=0.883
 <60 88 22 (53.7) 46 (52.3)  
 ≥60 41 19 (49.3) 42 (47.7)  
Gender    p=0.164
 Male 80 29 (70.7) 51 (58)  
 Female 49 12 (29.3) 37 (42)  
Smoking Status    p=0.062
 Smokers 82 31 (75.6) 51 (58.6)  
 Non-Smokers 46 10 (24.4) 36 (31.4)  
Alcohol Consumption    p=0.018
 Risk Drinker BAG 29 12 (41.4) 17 (58.6)  
  Non-Risk Drinker 
BAG 87 22 (25.3) 65 (74.7)  
  Suspended or no 
information 11 7 (63.6) 4 (36.4)  
Tumor Grading    p=0.549
 Well-differentiated 19 4 (9.8) 15 (17)  
  Moderately 
differentiated 87 29 (70.7) 58 (65.9)  
 Undifferentiated 23 8 (19.5) 15 (17.1)  
Tumor Staging    p=0.472
 pT1 56 15 (41.7) 41 (48.8)  
 pT2-4 65 21 (58.3) 44 (51.2)  
Nodal Status    p=0.153
 pN0 71 16 (48.5) 48 (63.2)  
 pN1-3 45 17 (51.5) 38 (36.8)  
Local Recurrence    p=0.224
 Yes 16 3 (7.3) 13 (14.9)  
 No 112 38 (92.7) 74 (85.1)  
Nodal Recurrence    p=0.098
 Yes 14 7 (17.1) 7 (8)  
 No 114 34 (82.9) 80 (92)  
Perineural Invasion    p=0.851
 Yes 38 12 (34.3) 26 (32.5)  
 No 77 23 (65.7) 54 (67.5)  
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Figure 1: Kaplan Meier curve showing a statistically significantly improved OS for patients with negative compared 
to positive CK19 immunoreactivity of their tumors; p<0.00.
No significant difference could be shown for 
DFS between patients with positive and negative CK19 
immunoreactivity (p=.094).
To investigate a possible association between CK19 
and other known predictive biomarkers in HNSCC we ran 
a Spearman’s rho correlation and only found a significant 
correlation for CK19 and Ki-67 (p=.010, R=.227).
DISCUSSION
CK19 is an acidic protein of 40 kDa that is part 
of the cytoskeleton of epithelial cells. The expression 
depends mainly on the epithelium type and on the status 
of epithelial terminal differentiation and maturation. 
Furthermore, this smallest known acidic cytokeratin is 
not paired with a basic cytokeratin in epithelial cells. It 
is specifically expressed in the periderm, the transiently 
superficial layer that envelops the developing epidermis 
[15]. CK19 is expressed in simple epithelium and the basal 
cells of squamous epithelium and is mainly interpreted as 
a marker of dysfunctional epithelial differentiation [8], 
however the underlying biology is still poorly understood.
The present retrospective study examined the effect 
of CK19 on overall and disease specific survival of an oral 
tongue cancer cohort. We found that patients with positive 
CK19 staining in oral tongue HNSCC had a worse 
outcome regarding overall and disease specific survival 
than patients with negative CK19 staining. Our findings 
are in line with other studies that found that increased 
CK19 expression in locally advanced HNSCC cases 
is related to decreased survival [14]. This is, however, 
the first organ specific study (solely oral tongue cancer 
patients) demonstrating the significant predictive value of 
CK19 in tumor tissue.
The mucosal lining of a large part of the human 
oral epithelium is non-keratinized, but can undergo 
abnormal keratinization in premalignant and malignant 
(e.g. squamous cell carcinoma) lesions of the oral mucosa. 
These changes in the patterns of keratinization are 
accompanied by changes in the expression of cytokeratins 
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Table 2: Significant factors negatively affecting the outcome of OS
Risk Men ≥60y Smokers Non Smokers Risk Drinker
pT2-
4b
pN1-
3a Tumor Grade 2
No Perineural 
Invasion
p .002 .001 .017 .015 .012 .022 .027 .009 <.000
Figure 2: Kaplan Meier curve showing a statistically significantly improved disease specific survival for patients with 
negative compared to positive CK19 immunoreactivity of their tumors; p=0.001.
and other biomarkers. In oral epithelium, the hard palate, 
attached gingiva, and dorsal tongue are keratinized, but the 
oral floor and buccal region are non-keratinized. Lingual 
keratinized epithelial cells, which constitute the filiform 
papillae of the tongue, have one of the most rapid tissue 
turnover rates in the mammalian body and are thought 
to be the source cells of squamous cell carcinoma of the 
tongue [16].
Ki-67 is a well-known cellular marker for 
proliferation and is absent in the resting phase of cells. 
It was selected in this study as the most referenced 
biomarker for proliferation and we found a significant 
correlation between CK19 and Ki-67. This correlation 
could possibly shed light on tumor aggressiveness and 
therapeutic response since an increased proliferation rate 
(Ki-67) is indicative of a worse prognosis [18–20].
Human Papilloma Virus (HPV) is not regarded as 
a major pathogen in oral cancer and as only five patients 
in this cohort showed a positivity to p16 the relationship 
to CK19, HPV and smoking was not explored further 
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[17]. Contrary to smoking, consuming alcohol appears 
to be associated with a higher expression of CK19. This 
has been seen in salivary glands of rats fed ethanol 
through gavage for 55 days [18]. A possible explanation 
may be the higher rate of dysplasia in alcohol users 
versus the Non Drinkers, however, further investigation 
is required [19].
CYFRA 21-1 is the soluble fragment of CK19 and 
is released once CK19 is cleaved by caspase-3 during 
apoptosis. Other studies showed a positive correlation 
between salivary and serum CYFRA 21-1 and CK19 
mRNA and protein expression [9, 14]. In this study 
CK19 expression did not have a significant correlation 
to tumor size or tumor stage. This discrepancy between 
the positive correlation of CK 19 to poor OS, DSS 
and tumor proliferation rate (Ki-67) as well as non-
correlation to tumor stage may indicate that CK 19 is a 
surrogate marker for invasiveness or tumor aggression. 
Moreover, our results are to a certain extent comparable 
to Malhotra et al., who found no correlation between 
CK19 mRNA levels and recurrence or tumor grade. 
However, our results do show a significant correlation 
to DSS which may implicate tumor persistence, 
recurrence or metastasis [9]. Though, the relationship 
between CK19 tissue expression and CYFRA 21-1 
levels in body fluid is still heterogeneously discussed. 
CYFRA 21-1 levels in serum tend to be sensitive, but 
salivary CYFRA 21-1 appears to be the most sensitive, 
thus salivary CYFRA 21-1 levels combined with CK19 
immunohistochemistry could reflect the prognosis more 
accurately [9].
In conclusion, our results from 129 patients with 
oral tongue cancer showed a highly significant association 
of CK19 positive immunoreactivity to overall survival and 
disease specific survival. We further found a significant 
correlation between CK19 and Ki-67 which indicates 
some interrelationship of CK19 to the higher turnover in 
certain tumors.
This is of special importance against the 
background that both high proliferation rate (Ki-67) 
and CK19 positive carcinomas revealed a significantly 
poorer prognosis that may indicate a more invasive 
and aggressive tumor behavior. The role of Ki-67 and 
CK19 and its serum fragments CYFRA 21-1 for use 
in individual tumor diagnosis and prognosis should be 
explored prospectively.
MATERIALS AND METHODS
Patients
A total of 229 tongue cancer (excluding tongue 
base) patients who fulfilled the inclusion criteria were 
identified in the data search. 129 patients had suitable 
material for inclusion in a tissue microarray (TMA) 
and were included in this retrospective study. Where 
possible, samples were taken from central and peripheral 
regions of the tumor to generate a representative sample 
of the tumor. All of the patients gave their consent for 
data search, use of biological material and further use of 
their data when they were admitted to the hospital. The 
study was approved by the Cantonal Ethic Commission 
Zurich (KEK-ZH-Nr. 2013-0298) and cause and dates 
of death were sourced from the Cancer Registry at the 
University Hospital Zurich. The median follow-up time 
was 36 months.
Inclusion criteria
All tongue cancer patients, older than 18 years, 
treated at the Department of Cranio-, Maxillofacial and 
Oral Surgery and/or the Department of Otolaryngology, 
Head and Neck Surgery and/or the Department of 
Radiation-oncology and/or the Department of Medical 
Oncology at the University Hospital Zurich from 2005 
to 2014 were included in the study. The defined oral 
tongue cancer did not include the base of the tongue and 
could be defined as primary cancer of the oral tongue 
and was distinguishable from primary floor of mouth 
cancer.
Study variables
Clinical data and personal information pertaining 
to family history, and use of alcohol and tobacco were 
obtained through a comprehensive review of medical 
records. Alcohol consumption was divided into three 
groups: Drinkers, which included occasional as well as 
regular drinkers (Risk Drinker, Bundesamt für Gesundheit 
(BAG), Switzerland) and Non-Drinkers including 
patients who never drank alcohol (Non-Risk Drinker, 
BAG), or those who stopped drinking alcohol at least one 
year before diagnosis or no information was available. 
Table 3: Significant negatively factors affecting the outcome of DSS
Risk Men ≥60y Smokers Non Smokers Non Risk  
Drinker
pT1 Tumor Grade 2
p <.000 .001 .040 .010 .007 .011 .036
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Smoking status was divided into two groups: Smokers, 
which included patients who smoked regardless of the 
pack years, and patients who stopped smoking less than 
one year before diagnosis and Non-Smokers including 
patients who had never smoked.
Tissue microarrays and immunohistochemistry
Tissue microarrays were constructed from 
paraffin-embedded (FFPE) tissue as previously 
described [20]. Tumor tissue blocks were collected 
from the Institute of Surgical Pathology, University 
Hospital Zurich, Switzerland and selection was based 
on availability, quality and size of tumor tissue on the 
paraffin block.
For immunohistochemical studies, consecutive 3 
μm-sections were freshly cut from paraffin TMA tissue 
blocks. Stainings were performed on an automated 
staining system (Ventana BenchMark ULTRA, Roche-
Ventana Medical Systems, Tucson, AZ, USA) according 
to the manufacturers’ instructions. Cytokeratin 19: 
Pretreatment Protease1 for 4min, mouse monoclonal 
anti-Cytokeratin 19 (RCK108) antibody (Abcam plc, 
Cambridge, UK) for 16min; Ki-67: Pretreatment Cell 
Conditioning 1 (CC1) for 32min, rabbit monoclonal 
anti-Ki-67 (30-9) antibody (Roche-Ventana Medical 
Systems, Tucson, AZ, USA). For analyses of Cytokeratin 
19 a semi-quantitative four-step scoring system (0-3) 
was used based on the staining intensity of the tumor 
tissue: 0 = negative; 1 = weak positive; 2 = intermediate 
positive; 3 = strong positive. CK19 positive refers to 
scores 1-3 and CK19 negative to score 0 (Figure 3). For 
Ki-67 the percentage of stained nuclei of tumor cells 
was recorded.
Statistical analysis
The primary endpoint was overall survival (OS) 
as measured as the time from the date of diagnosis to 
the date of death or date of last contact. Secondary 
endpoints were disease free survival (DFS) measured as 
the time from the end of treatment to date of relapse, 
recurrence or distant metastasis and disease specific 
survival (DSS), which was measured as the time from 
the date of diagnosis to the date of death where the cause 
of death was disease specific.
Pearson’s Chi-Square was applied to evaluate how 
likely it is that any observed difference between the sets 
of categorical data arose by chance (p<.05). Survival 
was calculated using Kaplan-Meier curves. Multivariate 
analysis was performed using Cox Regression (p<.05). All 
statistical analyses were performed using SPSS 22 (IBM 
Corp. Released 2013. IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, NY: IBM Corp.).
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Figure 3: A–B. Expression of Cytokeratin 19 in oral squamous cell carcinoma: (A) immunohistochemical staining for CK19 with 
negative tumor tissue versus (B) strong positivity in other representative samples of malignant tumors, surrounding stromal tissue remains 
unstained. Scale bar = 100 μm.
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